NeuroNova Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $19.1M

NeuroNova General Information

Description

Developer and provider of novel therapies for the treatment of disorders of the central nervous system. The company also develops novel therapeutic products based on neurogenesis in areas of high unmet medical need in neurodegenerative diseases.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Fiskartorpsvägen 15 A-D
  • SE-114 33 Stockholm
  • Sweden
+46 08-786 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NeuroNova Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 17-Dec-2012 $19.1M 000.00 000.00 Completed Generating Revenue
5. Grant 01-Jan-2008 00000 000.00 Completed Product Development
4. Later Stage VC 01-Feb-2007 000.00 000.00 Completed Product Development
3. Early Stage VC 10-Sep-2003 000.00 000.00 Completed Product Development
2. Early Stage VC 20-Mar-2000 $3.45M $3.45M Completed Product Development
1. Seed Round Completed Startup
To view NeuroNova’s complete valuation and funding history, request access »

NeuroNova Patents

NeuroNova Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-2101806-A2 Treatment of disease or injury of the nervous system using agents that decrease the activity of the melanocortin 4 receptor Active 14-Dec-2006 000000000
EP-2101806-B1 Treatment of parkinson's disease or parkinsonian disorders using agents that decrease the activity of the melanocortin 4 receptor Inactive 14-Dec-2006 000000000
CA-2672524-A1 Treatment of disease or injury of the nervous system using agents that decrease the activity of the melanocortin 4 receptor Active 14-Dec-2006 000000000
CA-2672524-C Treatment of disease or injury of the nervous system using agents that decrease the activity of the melanocortin 4 receptor Inactive 14-Dec-2006 000000000
US-20100129319-A1 Treatment of disease or injury of the nervous system using agents that decrease the activity of the melanocortin 4 receptor Inactive 14-Dec-2006 A61K31/00
To view NeuroNova’s complete patent history, request access »

NeuroNova Executive Team (4)

Name Title Board Seat Contact Info
Anders Haegerstrand Chief Executive Officer
You’re viewing 1 of 4 executive team members. Get the full list »

NeuroNova Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
HealthCap Venture Capital Minority 000 0000 000000 0
Novare Kapital Venture Capital Minority 000 0000 000000 0
Patricia Industries PE/Buyout Minority 000 0000 000000 0
Scandinavian Life Science Venture Venture Capital Minority 000 0000 000000 0
To view NeuroNova’s complete investors history, request access »

NeuroNova FAQs

  • When was NeuroNova founded?

    NeuroNova was founded in 1998.

  • Who is the founder of NeuroNova?

    Jonas Frisén is the founder of NeuroNova.

  • Who is the CEO of NeuroNova?

    Anders Haegerstrand is the CEO of NeuroNova.

  • Where is NeuroNova headquartered?

    NeuroNova is headquartered in Stockholm, Sweden.

  • What industry is NeuroNova in?

    NeuroNova’s primary industry is Drug Discovery.

  • Is NeuroNova a private or public company?

    NeuroNova is a Private company.

  • What is the current valuation of NeuroNova?

    The current valuation of NeuroNova is 000.00.

  • What is NeuroNova’s current revenue?

    The current revenue for NeuroNova is 00000.

  • How much funding has NeuroNova raised over time?

    NeuroNova has raised $27.3M.

  • Who are NeuroNova’s investors?

    HealthCap, Novare Kapital, Patricia Industries, and Scandinavian Life Science Venture have invested in NeuroNova.

  • When was NeuroNova acquired?

    NeuroNova was acquired on 17-Dec-2012.

  • Who acquired NeuroNova?

    NeuroNova was acquired by Newron Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »